Prurigo nodularis Market: F: Information, Figures and Analytical Insights 2021-2030

The Prurigo nodularis Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. We analyzed the impact of COVID-19 (Corona Virus) on the product industry chain based on the upstream and downstream markets, on various regions and major countries and on the future development of the industry are pointed out.

Click the link to get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/10232393792/prurigo-nodularis-pipeline-insight-2020/inquiry?Mode=12      

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Prurigo nodularis Market: Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho and others. 

IL-31 Drug Succeeds for Prurigo Nodularis

February 19, 2020: An investigational monoclonal antibody targeting interleukin-31 (IL-31) receptor A improved symptoms of moderate-to-severe prurigo nodularis (PN) in a small randomized trial.

After only 4 weeks, PN patients assigned to subcutaneous nemolizumab in the phase II study had a significant reduction in their pruritus score compared with those on placebo, meeting the trial's primary endpoint, reported Sonja Ständer, MD, of University Hospital Münster in Germany, and colleagues.

EMA's human medicines committee recommends approval of Dupixent for children aged 6 to 11 years with severe atopic dermatitis

October 19, 2020: The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent (dupilumab), recommending to extend the approval in the European Union (EU) to include children aged 6 to 11 years with severe atopic dermatitis who are candidates for systemic therapy. Dupixent is the first and only biologic approved for the treatment of uncontrolled moderate-to-severe atopic dermatitis for ages 12+ in the EU and ages 6+ in the US.

Dupixent is also approved in the EU for certain patients with severe asthma and severe chronic rhinosinusitis with nasal polyps, two other type 2 inflammatory diseases. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. The positive CHMP opinion is supported by data that include pivotal Phase 3 results on the efficacy and safety of Dupixent combined with TCS in children aged 6 to 11 years with severe atopic dermatitis that is uncontrolled on topical prescription therapies. In the trial, children treated with Dupixent and TCS experienced significantly improved measures of overall disease severity (Eczema Area and Severity Index), skin clearance, itch and health-related quality of life measures, compared to TCS alone.

Buy This Report:

https://www.marketinsightsreports.com/report/purchase/10232393792?mode=su?Mode=12      

Overview:

Prurigo nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules) to form on the skin. The itching (pruritus) can be intense, causing people to scratch themselves to the point of bleeding or pain. Scratching can cause more skin lesions to appear. The itching is worsened by heat, sweating, or irritation from clothing.[4] In some cases, people with PN have a history of other diseases including eczema (atopic dermatitis), lymphoma, HIV infection, severe anemia, or kidney disease.

The exact cause of PN is unknown. Although scratching is known to cause more nodules to appear, it is unclear what causes the itching to develop in the first place.

Key Products

Serlopitant
Nemolizumab
KPL-716
SAR231893
M118103

Influence Of The Prurigo nodularis Market Report:

-Comprehensive assessment of all opportunities and risk in the Prurigo nodularis market.

- Prurigo nodularis market recent innovations and major events.

-A Detailed study of business strategies for growth of the Prurigo nodularis market-leading players.

-Conclusive study about the growth plot of Prurigo nodularis market for forthcoming years.

-In-depth understanding of Prurigo nodularis market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Prurigo nodularis market.

What Are The Market Factors That Are Explained In The Report?

Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Analytical Tools: The Global Prurigo nodularis Market Report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter’s five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

The report has 150 tables and figures browse the report description and TOC:

https://www.marketinsightsreports.com/reports/10232393792/prurigo-nodularis-pipeline-insight-2020?Mode=12

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

Please connect with our sales team (sales@marketinsightsreports.com).

Contact Us:

Irfan Tamboli (Head of Sales) - Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.